Mineralys Therapeutics Publishes Presentation on Lorundrostat in Chronic Kidney Disease

• Mineralys Therapeutics published a presentation on lorundrostat's blood pressure and albuminuria effects in chronic kidney disease in the Phase 3 Launch-HTN trial.
• Lorundrostat 50 mg daily produced statistically significant reductions in systolic blood pressure and urinary albumin-to-creatinine ratio in the CKD subgroup.
• The CKD subgroup included 192 participants with stages 1-3 disease; blood pressure responses did not differ significantly from participants without CKD.
• Across the overall trial, 50 mg lowered systolic blood pressure by 19.0 mmHg at 12 weeks, a placebo-adjusted reduction of 11.6 mmHg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.